A detailed history of Aqr Capital Management LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Aqr Capital Management LLC holds 536,114 shares of VRTX stock, worth $254 Million. This represents 0.39% of its overall portfolio holdings.

Number of Shares
536,114
Previous 666,691 19.59%
Holding current value
$254 Million
Previous $279 Million 9.83%
% of portfolio
0.39%
Previous 0.48%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$392.81 - $485.53 $51.3 Million - $63.4 Million
-130,577 Reduced 19.59%
536,114 $251 Million
Q1 2024

May 15, 2024

BUY
$407.69 - $446.08 $8.94 Million - $9.78 Million
21,923 Added 3.4%
666,691 $279 Million
Q4 2023

Feb 14, 2024

BUY
$343.0 - $410.68 $435,953 - $521,974
1,271 Added 0.2%
644,768 $262 Million
Q3 2023

Nov 14, 2023

BUY
$338.18 - $362.46 $10.5 Million - $11.3 Million
31,067 Added 5.07%
643,497 $224 Million
Q2 2023

Aug 14, 2023

BUY
$314.42 - $351.91 $12.9 Million - $14.4 Million
40,915 Added 7.16%
612,430 $216 Million
Q1 2023

May 15, 2023

SELL
$283.23 - $323.1 $4.55 Million - $5.2 Million
-16,079 Reduced 2.74%
571,515 $180 Million
Q4 2022

Feb 14, 2023

BUY
$285.76 - $321.48 $26.6 Million - $29.9 Million
93,063 Added 18.82%
587,594 $170 Million
Q3 2022

Nov 14, 2022

SELL
$273.83 - $305.53 $6.09 Million - $6.8 Million
-22,253 Reduced 4.31%
494,531 $143 Million
Q2 2022

Aug 15, 2022

BUY
$234.96 - $292.55 $3.96 Million - $4.93 Million
16,840 Added 3.37%
516,784 $144 Million
Q1 2022

May 16, 2022

SELL
$221.42 - $260.97 $21.8 Million - $25.7 Million
-98,539 Reduced 16.46%
499,944 $129 Million
Q4 2021

Feb 14, 2022

SELL
$177.01 - $223.45 $7.23 Million - $9.12 Million
-40,834 Reduced 6.39%
598,483 $131 Million
Q3 2021

Nov 15, 2021

SELL
$181.39 - $202.99 $12.2 Million - $13.7 Million
-67,436 Reduced 9.54%
639,317 $116 Million
Q2 2021

Aug 16, 2021

SELL
$187.49 - $221.1 $38.2 Million - $45.1 Million
-203,774 Reduced 22.38%
706,753 $139 Million
Q1 2021

May 17, 2021

BUY
$207.02 - $241.31 $72.5 Million - $84.5 Million
350,146 Added 62.48%
910,527 $195 Million
Q4 2020

Feb 16, 2021

SELL
$207.01 - $276.09 $17.4 Million - $23.2 Million
-83,887 Reduced 13.02%
560,381 $129 Million
Q3 2020

Nov 16, 2020

BUY
$255.65 - $303.1 $8.3 Million - $9.84 Million
32,453 Added 5.3%
644,268 $175 Million
Q2 2020

Aug 17, 2020

BUY
$225.48 - $295.8 $3.82 Million - $5.01 Million
16,945 Added 2.85%
611,815 $176 Million
Q1 2020

May 15, 2020

BUY
$199.77 - $247.81 $36.9 Million - $45.7 Million
184,560 Added 44.98%
594,870 $138 Million
Q4 2019

Feb 14, 2020

BUY
$166.71 - $223.91 $23 Million - $30.9 Million
138,186 Added 50.78%
410,310 $89.6 Million
Q3 2019

Nov 14, 2019

BUY
$166.23 - $187.09 $3.68 Million - $4.15 Million
22,158 Added 8.86%
272,124 $45.8 Million
Q2 2019

Aug 14, 2019

SELL
$164.61 - $190.37 $32 Million - $37 Million
-194,184 Reduced 43.72%
249,966 $45 Million
Q1 2019

May 14, 2019

SELL
$163.73 - $194.7 $51.6 Million - $61.3 Million
-314,883 Reduced 41.48%
444,150 $81 Million
Q4 2018

Feb 14, 2019

SELL
$151.91 - $192.21 $79.3 Million - $100 Million
-522,311 Reduced 40.76%
759,033 $126 Million
Q3 2018

Nov 15, 2018

BUY
$167.73 - $192.74 $75.4 Million - $86.6 Million
449,549 Added 54.05%
1,281,344 $247 Million
Q2 2018

Aug 14, 2018

SELL
$145.72 - $169.96 $63 Million - $73.5 Million
-432,617 Reduced 34.21%
831,795 $141 Million
Q1 2018

May 15, 2018

SELL
$151.6 - $177.13 $38.4 Million - $44.9 Million
-253,423 Reduced 16.7%
1,264,412 $206 Million
Q4 2017

Feb 14, 2018

SELL
$137.28 - $155.55 $51.2 Million - $58 Million
-372,855 Reduced 19.72%
1,517,835 $227 Million
Q3 2017

Nov 14, 2017

BUY
$148.13 - $162.24 $280 Million - $307 Million
1,890,690
1,890,690 $287 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $122B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Aqr Capital Management LLC Portfolio

Follow Aqr Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aqr Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Aqr Capital Management LLC with notifications on news.